Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SSGJ-709 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on SSGJ-709, a putative bispecific antibody targeting CD274 (PD-L1) and LAG3 (Jun 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SSGJ-709 | SSGJ 709|SSGJ709 | LAG3 Antibody 19 PD-L1/PD-1 antibody 132 | Limited information is currently available on SSGJ-709, a putative bispecific antibody targeting CD274 (PD-L1) and LAG3 (Jun 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07016490 | Phase I | SSGJ-709 | A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors | Recruiting | AUS | 0 |